Cost-Effectiveness Analysis of Liraglutide Versus Insulin Glargine in Chinese Patients with Type 2 Diabetes Insufficiently Controlled on Metformin

X. Gu,F. Liu,P. Men,S. Zhai

DOI: https://doi.org/10.1016/j.jval.2018.04.502

IF: 5.156

2018-01-01

Value in Health

Abstract:To evaluate the long-term economic and health outcomes associated with once daily liraglutide 1.2 mg versus insulin glargine in Chinese patients with Type 2 Diabetes Mellitus (T2DM) inadequately controlled with metformin. The published and validated CORE diabetes model was used to evaluate the long-term clinical and economic outcomes of liraglutide and insulin glargine. Simulated cohorts and treatment effects were derived from a clinical trial comparing liraglutide 1.2mg once daily and insulin glargine both in combination use with metformin in Chinese T2DM patients. Treatment cost was derived from drug retail price in Chinese market. Diabetes management and complication costs were obtained from Chinese published data. Projections were made from a societal perspective for a 30-year time horizon and an annual discounting rate of 3% was used for both costs and health outcomes simulation. One-way sensitivity analyses and probabilistic sensitivity analyses were performed. Long term projections (30 years) demonstrated that compared with insulin glargine, liraglutide 1.2 mg was associated with lower cumulative incidences of diabetes complications and improved long term health outcomes for patients with T2DM. Compared with insulin glargine, the cumulative incidences of diabetic foot ulcer, angina pectoris, and mild hypoglycemia with liraglutide were reduced by 1.93%, 1.72% and 1.66%, respectively. Liraglutide 1.2mg was associated with improvements of 0.347 quality-adjusted life years (QALYs) versus insulin glargine, a total direct medical cost saving of 10,030 CNY, and an incremental cost-effectiveness (ICER) of -28,904 CNY/QALY in a 30-year projection horizon. These results indicated that liraglutide 1.2 mg was cost saving in comparison with insulin glargine for the treatment of T2DM not adequately controlled with metformin in China. Sensitivity analyses demonstrated the robustness of results. The treatment of liraglutide 1.2 mg improved patient health and economic outcomes versus insulin glargine, and was a dominant treatment approach in Chinese T2DM patients.